BioNTech Escalates Legal Battle Over mRNA Vaccine Patents

BioNTech escalates the mRNA patent war, filing a new lawsuit against Moderna's mNEXSPIKE vaccine. The legal battle centers on foundational technology with major financial stakes for future vaccine sales.

The ongoing intellectual property dispute between leading mRNA vaccine developers has intensified. BioNTech SE has initiated a new legal offensive against its rival Moderna, centering on the foundational technology behind their COVID-19 vaccines. This move marks a significant escalation in a complex patent war with substantial financial implications for future vaccine revenues.

A Counter-Lawsuit in Delaware

On Thursday, February 19, BioNTech filed a complaint against Moderna in a U.S. federal court located in Delaware. The core allegation is that Moderna has infringed upon patents related to BioNTech's Comirnaty vaccine platform.

Specifically, the legal action targets Moderna's mNEXSPIKE vaccine, which source material indicates received FDA approval in 2025. BioNTech contends that this competitor product utilizes a proprietary, "streamlined" mRNA design intended to enable effective immunization with lower doses. The company asserts this technology is being used without a proper licensing agreement.

This latest filing is widely viewed as a direct countermove. It follows Moderna's own 2022 patent infringement lawsuit against BioNTech and its partner Pfizer, which also revolved around mRNA and vaccine-related intellectual property.

Financial Stakes and Industry Trends

Court documents reveal BioNTech's assessment of the financial impact. The company anticipates that mNEXSPIKE could constitute a major portion of Moderna's COVID-19 vaccine sales during the crucial 2025–2026 respiratory season. This timing amplifies the stakes; high sales from an allegedly infringing product during a peak season quickly raise the prospect of costly licensing fees, retroactive payments, or complex settlement negotiations.

Market observers are primarily focused on two potential outcomes from such litigation: negotiated royalty settlements or cross-licensing agreements. This case fits a broader industry pattern. Patent disputes within the biotech sector have become more frequent since the pandemic, as firms more aggressively defend the intellectual property rights they established during that period.

Share Performance and Strategic Pivot

Despite the legal developments, BioNTech shares demonstrated relative resilience in the market. According to provided data, the stock was quoted at €92.55 on Friday, representing a decline of 1.28%.

Parallel to this legal contest, BioNTech continues to execute its strategic shift toward oncology. The company's financial foundation for this transition is robust, with approximately €17.2 billion in cash, cash equivalents, and security investments as of December 31, 2025. This substantial reserve is earmarked to help fund a pipeline of cancer immunotherapies. The long-term objective is to transform into a multi-product oncology company by 2030, thereby reducing dependence on revenue from respiratory vaccines.

The immediate next step, however, is the legal process itself. With the complaint now filed and the dispute clearly defined, the coming months will determine whether the conflict heads toward a definitive court ruling or culminates in a negotiated licensing or settlement agreement.